Aberrant muscle antigen exposure in mice is sufficient to cause myositis in a treg cell-deficient milieu

Arthritis and Rheumatism

Volumn 65, Issue 12, 2013, Pages 3259-3270

  Young, Nicholas A ^a   Sharma, Rahul ^b   Friedman, Alexandra K ^a   Kaffenberger, Benjamin H ^a   Bolon, Brad ^a   Jarjour, Wael N ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCLE ANTIGEN; MYOSIN; RAG1 PROTEIN; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR FOXP3;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; FEMALE; INFLAMMATORY CELL; LYMPH NODE CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MEMBRANE DAMAGE; MOUSE; MUSCLE INJURY; MUSCLE TISSUE; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; REGULATORY T LYMPHOCYTE; SKELETAL MUSCLE;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; INFLAMMATION; MICE; MUSCLE, SKELETAL; MYOSITIS; T-LYMPHOCYTES, REGULATORY;

EID: 84889053586     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38184     Document Type: Article

References (45)

1. Figarella-Branger D, Civatte M, Bartoli C, Pellissier JF,. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28: 659-82.
2. Christopher-Stine L, Plotz PH,. Myositis: an update on pathogenesis. Curr Opin Rheumatol 2004; 16: 700-6.
3. Sontheimer RD,. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother 2004; 5: 1083-99.
4. Greenberg SA,. Inflammatory myopathies: evaluation and management. Semin Neurol 2008; 28: 241-9.
5. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314-24.
6. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-7.
7. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN,. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66: 1245-7.
8. Dalakas MC,. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies [published erratum appears in Nat Clin Pract Rheumatol 2006;2:398]. Nat Clin Pract Rheumatol 2006; 2: 219-27.
9. Martens S, Kozlov MM, McMahon HT,. How synaptotagmin promotes membrane fusion. Science 2007; 316: 1205-8.
10. Andrews NW,. Membrane repair and immunological danger. EMBO Rep 2005; 6: 826-30.
11. Chakrabarti S, Kobayashi KS, Flavell RA, Marks CB, Miyake K, Liston DR, et al. Impaired membrane resealing and autoimmune myositis in synaptotagmin VII-deficient mice. J Cell Biol 2003; 162: 543-9.
12. Sharma R, Sung SS, Fu SM, Ju ST,. Regulation of multi-organ inflammation in the regulatory T cell-deficient scurfy mice. J Biomed Sci 2009; 16: 20.
13. La Cava A,. The busy life of regulatory T cells in systemic lupus erythematosus. Discov Med 2009; 8: 13-7.
14. Le Bras S, Geha RS,. IPEX and the role of Foxp3 in the development and function of human Tregs. J Clin Invest 2006; 116: 1473-5.
15. Sharma R, Zheng L, Guo X, Fu SM, Ju ST, Jarjour WN,. Novel animal models for Sjögren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice. J Autoimmun 2006; 27: 289-96.
16. Sharma R, Jarjour WN, Zheng L, Gaskin F, Fu SM, Ju ST,. Large functional repertoire of regulatory T-cell suppressible autoimmune T cells in scurfy mice. J Autoimmun 2007; 29: 10-9.
17. Klapczynski M, Gagne GD, Morgan SJ, Larson KJ, Leroy BE, Blomme EA, et al. Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models. J Pathol Inform 2012; 3: 20.
18. Kakulas BA,. In vitro destruction of skeletal muscle by sensitized cells. Nature 1966; 210: 1115-8.
19. Kalden JR, Williamson WG, Irvine WJ,. Experimental myasthenia gravis, myositis and myocarditis in guinea-pigs immunized with subcellular fractions of calf thymus or calf skeletal muscle in Freund's complete adjuvant. Clin Exp Immunol 1973; 13: 79-88.
20. Esiri MM, MacLennan IC,. Experimental myositis in rats. I. Histological and creatine phosphokinase changes, and passive transfer to normal syngeneic rats. Clin Exp Immunol 1974; 17: 139-50.
21. Esiri MM, MacLennan IC,. Experimental myositis in rats. II. The sensitivity of spleen cells to syngeneic muscle antigen. Clin Exp Immunol 1975; 19: 513-20.
22. Rosenberg NL, Ringel SP, Kotzin BL,. Experimental autoimmune myositis in SJL/J mice. Clin Exp Immunol 1987; 68: 117-29.
23. Nemoto H, Bhopale MK, Constantinescu CS, Schotland D, Rostami A,. Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis. Exp Mol Pathol 2003; 74: 238-43.
24. Dalakas MC,. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010; 10: 346-52.
25. Antiga E, Kretz CC, Klembt R, Massi D, Ruland V, Stumpf C, et al. Characterization of regulatory T cells in patients with dermatomyositis. J Autoimmun 2010; 35: 342-50.
26. Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H,. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010; 225: 137-42.
27. Billiau A, Matthys P,. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001; 70: 849-60.
28. Wada K, Ueno S, Hazama T, Ogasahara S, Kang J, Takahashi M, et al. Radioimmunoassay for antibodies to human skeletal muscle myosin in serum from patients with polymyositis. Clin Exp Immunol 1983; 52: 297-304.
29. Elst EF, Klein M, de Jager W, Kamphuis S, Wedderburn LR, van der Zee R, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58: 547-55.
30. Hohlfeld R, Engel AG, Ii K, Harper MC,. Polymyositis mediated by T lymphocytes that express the γ/δ receptor. N Engl J Med 1991; 324: 877-81.
31. Bruder J, Siewert K, Obermeier B, Malotka J, Scheinert P, Kellermann J, et al. Target specificity of an autoreactive pathogenic human γδ-T cell receptor in myositis. J Biol Chem 2012; 287: 20986-95.
32. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A,. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60: 3784-93.
33. Meriggioli MN, Sanders DB,. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol 2012; 8: 427-38.
34. Allenbach Y, Solly S, Gregoire S, Dubourg O, Salomon B, Butler-Browne G, et al. Role of regulatory T cells in a new mouse model of experimental autoimmune myositis. Am J Pathol 2009; 174: 989-98.
35. Sharma R, Sharma PR, Kim YC, Leitinger N, Lee JK, Fu SM, et al. IL-2-controlled expression of multiple T cell trafficking genes and Th2 cytokines in the regulatory T cell-deficient scurfy mice: implication to multiorgan inflammation and control of skin and lung inflammation [published erratum appears in J Immunol 2011;186:5012-3]. J Immunol 2011; 186: 1268-78.
36. Sharma R, Sung SS, Gaskin F, Fu SM, Ju ST,. A novel function of IL-2: chemokine/chemoattractant/retention receptor genes induction in Th subsets for skin and lung inflammation. J Autoimmun 2012; 38: 322-31.
37. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
38. null T cells. J Immunol 2009; 183: 4792-9.
39. Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60: 2903-13.
40. + regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int 2009; 76: 717-29.
41. D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, et al. CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 2009; 119: 2898-913.
42. + regulatory T cells contribute to adenosine-mediated resolution of acute lung injury. FASEB J 2013; 27: 2207-19.
43. Desreumaux P, Foussat A, Allez M, Beaugerie L, Hebuterne X, Bouhnik Y, et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 2012; 143: 1207-17.e2.
44. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921-8.
45. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL,. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17: 194-200.